Picture of Oxford Nanopore Technologies logo

ONT Oxford Nanopore Technologies News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMid CapSucker Stock

REG - Oxford Nanopore Tech - Expansion of leadership team

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240122:nRSV3756Aa&default-theme=true

RNS Number : 3756A  Oxford Nanopore Technologies plc  22 January 2024

Oxford Nanopore Technologies plc

Expansion of leadership team

22 January 2024

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the
"Group"), the company delivering a new generation of nanopore-based molecular
sensing technology, today announces the expansion of the leadership team to
support the business in its next phase of growth.

Following a comprehensive search process, Nick Keher has been appointed as
Chief Financial Officer ("CFO") and Director of Oxford Nanopore, effective 22
January 2024. Nick will succeed Tim Cowper, who moves into a new role as Chief
Operating Officer ("COO") after performing both the role of CFO and fulfilling
most of the responsibilities typically assigned to a COO for the past five
years.

Nick is an experienced life sciences CFO, having previously served as CFO of
Clinigen Group and Benevolent AI. Prior to his CFO roles he gained extensive
experience in the life sciences industry serving as Managing Director and Head
of the European healthcare equity research team at Royal Bank of Canada (RBC)
and before that held roles at Investec and GSK after switching from practising
pharmacy. Nick comes to the role with significant experience of financial
leadership of complex, scientific businesses, and has a deep understanding of
capital markets. In his role as CFO, Nick will have responsibility for the
Group's finance function and investor relations.

In his new role as COO, Tim Cowper will lead the development of Oxford
Nanopore's expanding international footprint and operations, including day to
day operational functions such as manufacturing, tech transfer, IT, supply
chain, global distribution, EHS and set up and management of international
facilities.

There will be a transition period to ensure a smooth handover and the
efficient completion of the Company's 2023 audit and full year financial
results. Going forward in his role as COO, Tim will continue to work closely
with the new CFO to drive operational performance and margin enhancement.

Gordon Sanghera, Chief Executive Officer of Oxford Nanopore, commented:

"We are delighted to welcome Nick as CFO. His experience and expertise of
public company financial leadership in an innovative business environment will
support our sustainable growth towards profitability. With his scientific
background, he also understands the specific opportunities for life science
companies. These combine with a passion to deliver impact for all of our
stakeholders. I am excited to be working with Nick to drive value creation in
the coming years."

"I would also like to thank Tim for his leadership as CFO - for not only
building and managing our financial function through our IPO process and
driving our transition to a public company, but also leading many aspects of
our operations in recent years. As we continue to scale the business and
enhance our supply chain to meet growing demand for our products, Tim's
expertise will continue to be a significant asset to the business, and I look
forward to continuing to work with him in his new role as COO"

Nick Keher, Chief Financial Officer of Oxford Nanopore, commented:

"This is a great opportunity to join a global life sciences company with a
unique, best-in-class technology platform and an ambitious vision for the
future. I am delighted to be joining Gordon and the team at such an exciting
time in the company's growth journey and I look forward to working together to
deliver the business strategy and to create long-term shareholder value."

Tim Cowper, Chief Operating Officer of Oxford Nanopore, commented:

"I am excited to be moving into this new COO role, which is critical as we
further develop our sophisticated operations to support expanding customer
demand. Now is a good time to enhance our management team to build on the
significant growth that we have achieved over the last five years. Nick's
diverse experience will help enable us to scale Oxford Nanopore to reach new
heights and I look forward to working with him in this next stage of our
development."

 

During the past five years, Nick Keher has been a director of Clinigen Group.
There are no further disclosures required in respect of this appointment
pursuant to Listing Rule 9.6.13.

 

 ENDS 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:         ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:              media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

Notes

Remuneration Arrangements

Nick Keher's remuneration arrangements have been set in accordance with the
Directors' Remuneration Policy detailed in the FY22 Annual Report.  Further
details will be set out in the Directors' Remuneration Report for FY23.

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The company
has developed a new generation of nanopore-based sensing technology that is
currently used for real-time, high-performance, accessible, and scalable
analysis of DNA and RNA. The technology is used in more than 120 countries,
to understand the biology of humans, plants, animals, bacteria, viruses and
environments as well as to understand diseases such as cancer. Oxford
Nanopore's technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture.  Oxford Nanopore Technologies products are intended for
molecular biology applications and are not intended for diagnostic purposes.
For more information please visit: www.nanoporetech.com
(http://www.nanoporetech.com)

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUGUGUPCPWG

Recent news on Oxford Nanopore Technologies

See all news